

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **CHANGE OF EXECUTIVE DIRECTOR AND PRESIDENT**

#### **CHANGE OF EXECUTIVE DIRECTOR AND PRESIDENT**

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from March 27, 2025:

- (i) Mr. Jeffrey R Lindstrom (“**Mr. Lindstrom**”) resigned as an executive Director, president of the Company (“**President**”), and a director and the general manager of Shanghai MicroPort CardioFlow Medtech Co., Ltd. (上海微创心通医疗科技有限公司) (“**MP CardioFlow**”); and
- (ii) Mr. Zhang Ruinian (張瑞年) (“**Mr. Zhang**”) has been appointed as an executive Director, President, and a director and the general manager of MP CardioFlow.

#### **Resignation of Executive Director and President**

The Board announces that, Mr. Lindstrom resigned as an executive Director, President, and a director and the general manager of MP CardioFlow with effect from March 27, 2025 as he would like to devote more time to his other commitments and engagements.

Mr. Lindstrom has confirmed to the Company that he does not have any disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and/or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its appreciation to Mr. Lindstrom for his valuable contributions to the Company during his tenure of office with the Board and the Company.

## Appointment of Executive Director and President

The Board announces that, Mr. Zhang has been appointed as an executive Director, President, and a director and the general manager of MP CardioFlow with effect from March 27, 2025.

The biographical details of Mr. Zhang are set out as follows:

Mr. Zhang, aged 61, has over 20 years of experience in the fields of cardiovascular, general surgery, orthopedics, neurosurgery and neurovascular, in vitro diagnosis, diabetes and medical analytical instruments. From January 2023 to May 2024, Mr. Zhang served as the vice president of Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司), whose shares are listed on the Stock Exchange (stock code: 9877), where he also served as a consultant from July 2024 to March 2025. From April 2021 to December 2022, Mr. Zhang served as the general manager of the Greater China region at Corcym Medical Technology (Shanghai) Co., Ltd. (恪心醫療科技(上海)有限公司). From April 2018 to June 2020, he served as the chief executive director of Suzhou Jiecheng Medical Technology Co., Ltd. (蘇州杰成醫療科技有限公司). Prior to that, he also held senior management positions in various well-known global and domestic companies, including Xi'an Janssen Pharmaceutical Co., Ltd. (西安楊森製藥公司), Rhone-Poulenc Rorer S.A (China) Limited (羅納普朗克(中國)公司), Medtronic (China) Co., Ltd. (美敦力中國有限公司), Baxter Healthcare Co., Ltd., Edward Lifesciences Corporation (愛德華生命科學公司), Applied Biosystems Inc. (美國應用生物系統公司), Johnson & Johnson Medical (China) Ltd. (強生(中國)醫療器材有限公司), MicroPort Scientific Corporation (微創醫療科學有限公司), whose shares are listed on the Stock Exchange (stock code: 0853), Alcon Vision Products (China) Co., Ltd. (愛爾康(中國)眼科產品有限公司), among others.

Mr. Zhang obtained his bachelor's degree in clinical medicine from the Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院) (formerly known as the Shanghai Second Medical University (上海第二醫科大學)) in July 1987, and his master's degree in business administration from the University of British Columbia in January 2004.

Mr. Zhang shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company ("**Articles of Association**").

Mr. Zhang has entered into a service agreement with the Company. The initial term of his service agreement shall commence from the date of the appointment as an executive Director and continue for a period of three years, and shall be subject to re-election as and when required under the Articles of Association and the Rules Governing the Listing of Securities on the Stock Exchange (“**Llisting Rules**”), until terminated in accordance with the terms and conditions of the service agreement or by either party giving to the other not less than 30 days’ prior notice in writing. Pursuant to his service agreement, he is not entitled to receive director’s fee from the Company. Mr. Zhang’s remuneration will be subject to annual review by the remuneration committee of the Company and the Board with reference to the Company’s remuneration policy, the prevailing market level and his responsibilities and performance.

Mr. Zhang confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or Controlling Shareholders; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Zhang that need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Mr. Zhang for joining as a member of the Board and the Company.

By Order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, PRC, March 27, 2025

*As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*